<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 24, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355143</url>
  </required_header>
  <id_info>
    <org_study_id>20-000685</org_study_id>
    <nct_id>NCT04355143</nct_id>
  </id_info>
  <brief_title>Colchicine to Reduce Myocardial Injury in COVID-19 (COLHEART-19)</brief_title>
  <acronym>COLHEART-19</acronym>
  <official_title>Open-label (Unblinded) Randomized Trial of Colchicine to Reduce Myocardial Injury in COVID-19 (COLHEART-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants will be randomized in a 1:1 ratio to receive Colchicine plus current care per
      UCLA treating physicians versus current care per UCLA treating physicians alone (control
      arm). Importantly, this adaptive trial design allows for patients in either study arm to
      receive other investigational drugs for COVID-19 as new science emerges.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 25, 2020</start_date>
  <completion_date type="Anticipated">April 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Random assignment to study arms in a 1:1 ratio</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum troponin level</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Maximum level of troponin among multiple measures taken during hospitalization and at 30 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delta (baseline to peak) troponin level</measure>
    <time_frame>Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized, First day of rehospitalization if admitted within 30 days of study enrollment</time_frame>
    <description>Change from initial troponin level to maximum level of troponin among measures taken during hospitalization and at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta (baseline to peak) brain natriuretic peptide (BNP) level</measure>
    <time_frame>Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized, First day of rehospitalization if admitted within 30 days of study enrollment</time_frame>
    <description>Change from baseline BNP level (Day 1) to maximum level of BNP among measures taken during hospitalization and at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular ejection fraction (LVEF) on echocardiography</measure>
    <time_frame>Baseline, Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta (baseline to peak) C-Reactive protein (CRP) inflammatory biomarker level</measure>
    <time_frame>Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized, First day of rehospitalization if admitted within 30 days of study enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta (baseline to peak) D-Dimer inflammatory biomarker level</measure>
    <time_frame>Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized, First day of rehospitalization if admitted within 30 days of study enrollment</time_frame>
    <description>D-Dimer is a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis, so named because it contains two D fragments of the fibrin protein joined by a cross-link</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Expected to be less than 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants requiring mechanical ventilation or ICU care</measure>
    <time_frame>During hospitalization, expected to be up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalization</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants released and re-admitted to the hospital within 30 days of enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Colchicine plus current care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine 0.6 mg po BID x 30 days plus current care per UCLA treating physicians</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Current care alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Current care per UCLA physicians alone (control arm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine Tablets</intervention_name>
    <description>COLCRYS (colchicine, USP) tablets for oral administration, containing 0.6 mg of the active ingredient colchicine USP, administered po every 12 hours x 30 days.</description>
    <arm_group_label>Colchicine plus current care</arm_group_label>
    <other_name>COLCRYS</other_name>
    <other_name>AR 374</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Current care per UCLA treating physicians</intervention_name>
    <description>Current care</description>
    <arm_group_label>Colchicine plus current care</arm_group_label>
    <arm_group_label>Current care alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cardiac injury, including any of the following:

               -  Elevated troponin level

               -  Elevated BNP level

               -  New ECG changes (ischemia or conduction issues)

               -  New arrhythmia on telemetry

               -  New drop in LVEF on echocardiogram

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Pregnancy, breastfeeding mothers, and women of childbearing age who are unable to use
             adequate contraception, which includes:

               -  Intrauterine devices (IUD), contraceptive implants, or tubal sterilization

               -  Hormone methods with a barrier method

               -  Two barrier methods

               -  If a partner's vasectomy is the chosen method of contraception, a hormone or
                  barrier method must also be used in conjunction

          -  Co-administration of CYPA3A4 and P-glycoprotein transport inhibitor

          -  History of end-stage renal disease (ESRD), cirrhosis, or neuromuscular disease

          -  History of severe hematologic disease or coagulation disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Ardehali, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amir B Rabbani, MD</last_name>
    <phone>310-517-8578</phone>
    <email>arabbani@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Reza Ardehali, MD, PhD</last_name>
    <phone>310-825-9011</phone>
    <email>rardehali@mednet.ucla.edu</email>
  </overall_contact_backup>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

